The effect of TP-3 (Arg-Lys-Asp), TP-4 (Arg-Lys-Asp-Val), and TP-5 on the metastatic capacity of intravenously injected Lewis lung tumor cells.
The oligopeptides Arg-Lys-Asp (TP-3), Arg-Lys-Asp-Val (TP-4), and Arg-Lys-Asp-Val-Tyr (TP-5) considered as the active short fragments of thymopoietin were administered (lo mg/kg) to C57B1 mice 24 hours before the intravenous inoculation of Lewis lung tumor (LLT) cells. A substantial decrease in lung metastasis number was observed as a result of treatment with all of the three oligopeptides. TP-3, TP-4, and TP-5 treatment decreased the immunosuppressive activity of Cyclophosphamid (240 mg/kg) given 96 hours before the inoculation of LLT cells. After thymectomy, performed eight days before the LLT inoculation, only TP-3 treatment resulted in the decrease of Cyclophosphamid immunotoxicity. A stimulating effect of TP-3 on T helper cell activity is assumed. The oligopeptides TP-3, TP-4, and TP-5 are recommended for clinical trial in case of malignant tumors and immunodeficiency.
Szende
B
B
First Institute of Pathology and Experimental Cancer Research of Semmelweis Medical University, Budapest, Hungary.
Lapis
K
K
Pal
K
K
Sipos
L
L
Denes
L
L
Kisfaludy
L
L
D000818:Animals; D003520:Cyclophosphamide / Q000494:pharmacology; D007165:Immunosuppression Therapy; D007275:Injections, Intravenous; D008175:Lung Neoplasms / Q000517:prevention & control / Q000556:secondary*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009362:Neoplasm Metastasis / Q000517:prevention & control; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D010446:Peptide Fragments / Q000627:therapeutic use*; D013934:Thymectomy; D016305:Thymopentin; D013946:Thymopoietins / Q000031:analogs & derivatives / Q000627:therapeutic use*; D013951:Thymus Hormones / Q000627:therapeutic use*
D010446:Peptide Fragments; D013946:Thymopoietins; D013951:Thymus Hormones; D003520:Cyclophosphamide; D016305:Thymopentin